DelistingJul 17, 2026, 04:12 PM
Dare Bioscience Receives Nasdaq Delisting Notice
AI Summary
Dare Bioscience, Inc. received a notice from Nasdaq on July 13, 2026, indicating non-compliance with Listing Rule 5550(b). This is due to the company's stockholders' equity being less than $2.5 million and not meeting alternative requirements of $35 million in market value or $500,000 in net income. The company's common stock is subject to delisting unless it timely requests a hearing. Dare Bioscience plans to request a hearing, which will temporarily stay the delisting process, but there is no guarantee of an extension or regaining compliance.
Key Highlights
- Dare Bioscience received a Nasdaq delisting notice on July 13, 2026.
- Company's stockholders' equity was less than $2.5 million.
- Did not meet alternative requirements of $35 million market value or $500,000 net income.
- Company no longer complies with Nasdaq Listing Rule 5550(b).
- Dare Bioscience intends to timely request a hearing before a Nasdaq Hearing Panel.
- Requesting a hearing will stay the suspension and delisting.
- No assurance that an extension will be granted or compliance regained.
Price Impact
More from DARE